BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC".
Di Giusto S, Toffoletti E, Bonifacio M, Binotto G, Miggiano MC, Calistri E, Stulle M, Ermacora A, Stella R, Scaffidi L, D'Amore F, Scotton G, Griguolo D, De Matteis G, Bertorelle R, Krampera M, Semenzato G, Fanin R, Damiani D, Tiribelli M.
Di Giusto S, et al. Among authors: scotton g.
Cancer Med. 2023 Feb;12(3):3180-3184. doi: 10.1002/cam4.5158. Epub 2022 Oct 8.
Cancer Med. 2023.
PMID: 36208021
Free PMC article.